Elastrin Therapeutics
Elastrin Therapeutics, Inc.
Elastrin Therapeutics, Inc. is an innovative biotechnology company dedicated to creating groundbreaking therapies aimed at reversing cardiovascular diseases and reinstating elasticity in damaged tissues and organs. By addressing the genetic and environmental factors leading to the deterioration of elastin, the company seeks to enhance the quality of life for patients suffering from related health issues.
Products & Team
ELT-001
ELT-001 is Elastrin Therapeutics' lead product candidate, featuring an innovative formulation of EDTA-loaded nanoparticles that are conjugated with a proprietary monoclonal antibody. This cutting-edge technology is designed to selectively target and eliminate harmful calcifications in areas where elastin has degraded, with the potential to significantly restore the elasticity of blood vessels and various organs.
ELT-001 directly addresses the degradation of elastin, which is a critical factor in the progression of cardiovascular disease, by not only alleviating symptoms but seeking to repair the underlying tissue damage.
Customers face multiple challenges, including the progressive nature of cardiovascular diseases, debilitating symptoms associated with arterial stiffness and calcification, and a current lack of effective long-term solutions to restore vascular health.